Search

Search Constraints

You searched for: Author/Creator Sriuranpong, Virote

Search Results

1. 399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial. (10th December 2020)

2. 399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial. (9th November 2020)

3. A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. (December 2019)

4. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Issue 10274 (13th February 2021)

5. Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial. (August 2021)

7. High dose radiation with chemotherapy followed by salvage esophagectomy among patients with locally advanced esophageal squamous cell carcinoma. Issue 3 (21st March 2017)

8. IDDF2019-ABS-0171 EUS-Guided radiofrequency ablation as adjunctive treatment for unresectable pancreatic cancer versus chemotherapy alone (ERAP). (June 2019)

9. Immunogenicity of ChAdOx1-nCoV-19 vaccine in solid malignancy patients by treatment regimen versus healthy controls: A prospective, multicenter observational study. (October 2022)

10. Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Primary results from PALOMA-4. (November 2022)